Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Keith J Benkov
Icahn School of Medicine at Mount Sinai,
1 Gustave Levy Place, Box 1656, New York, NY 10029
Tanzania
Research Article
The Use of Concomitant Immunomodulators with Adalimumab Therapy in Pediatric Crohn’s Disease
Author(s): Keith J Benkov, George H Russell, Charles M Samson, Steven J Steiner, Eileen C King, Jesse Pratt, Samantha F Eichner, Richard B Colletti and ImproveCareNow NetworkKeith J Benkov, George H Russell, Charles M Samson, Steven J Steiner, Eileen C King, Jesse Pratt, Samantha F Eichner, Richard B Colletti and ImproveCareNow Network
Objectives: Adalimumab is an effective treatment for Crohn’s disease but antibody development may cause loss of response. Concomitant use of an immunomodulator reduces the development of antibodies. We performed a 5- year cross-sectional study of variation in use of adalimumab and concomitant therapy in a large pediatric population.Methods: We identified patients with Crohn’s disesae aged <18 years in the ImproveCareNow registry who received adalimumab between June 2010 through May 2015, and determined the rates of treatment with adalimumab and concomitant therapy with thiopurine or methotrexate, including variation by age, sex, geographical region and annual change. Chi-square tests compared percentages and the Cochran Armitage Trend Test tested percentages over time and across age groups.Results: Of 7,271 .. View More»
DOI:
10.4172/2155-9899.1000541